表紙
市場調查報告書

梅尼爾氏症:開發平台分析

Meniere Disease - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 321916
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
梅尼爾氏症:開發平台分析 Meniere Disease - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 45 Pages
簡介

梅尼爾氏症是會引起非自主性暈眩的內耳障礙,會出現聽障、耳鳴、耳朵閉塞感等症狀。原因有過敏,病毒感染,頭部外傷,偏頭痛等。

本報告提供梅尼爾氏症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

梅尼爾氏症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

開發治療藥的企業

  • Orbis Biosciences, Inc.
  • Otonomy, Inc.
  • Quark Pharmaceuticals, Inc.
  • Sound Pharmaceuticals, Inc.
  • Synphora AB

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • betamethasone valerate ER
  • dexamethasone acetate SR
  • latanoprost
  • OR-105
  • QPHL-2
  • SPI-1005

最新的開發平台資訊

暫停中的計劃

產品開發的里程碑

  • 關注的新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11560IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meniere Disease - Pipeline Review, H2 2019, provides an overview of the Meniere Disease (Ear Nose Throat Disorders) pipeline landscape.

Meniere disease is a disorder of the inner ear that causes spontaneous episodes of vertigo. Signs and symptoms of Meniere disease are hearing loss, tinnitus and feeling of fullness in the ear. Causes include allergies, viral infection, head trauma and migraines.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meniere Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Meniere Disease (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meniere Disease (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Unknown stages are 2, 1, 2 and 1 respectively.

Meniere Disease (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Meniere Disease (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Meniere Disease (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Meniere Disease (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Meniere Disease (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Meniere Disease (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Meniere Disease - Overview
  • Meniere Disease - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Meniere Disease - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Meniere Disease - Companies Involved in Therapeutics Development
    • IntraBio Ltd
    • Orbis Biosciences Inc
    • Otonomy Inc
    • Quark Pharmaceuticals Inc
    • Sound Pharmaceuticals Inc
    • Synphora AB
  • Meniere Disease - Drug Profiles
    • betamethasone valerate ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexamethasone SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ebselen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IB-2000s - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QPHL-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Meniere Disease - Dormant Projects
  • Meniere Disease - Product Development Milestones
    • Featured News & Press Releases
      • Sep 18, 2019: FDA grants Fast Track Designation for SPI-1005 in the treatment of Meniere's Disease
      • Jun 25, 2019: Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere's Disease clinical trial
      • Mar 20, 2019: Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere's Disease clinical trial
      • Mar 06, 2019: Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere's Disease clinical trial
      • Feb 06, 2019: Otonomy announces presentation on OTIVIDEX at Association for Research in Otolaryngology Annual Meeting
      • Oct 02, 2018: Otonomy announces OTIVIDEX data presentation at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
      • Jul 26, 2018: Otonomy Initiates Phase 3 Clinical Trial of OTIVIDEX in Meniere Disease
      • Nov 08, 2017: Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX in Patients with Meniere's Disease
      • Oct 03, 2017: Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Menieres Disease
      • Aug 30, 2017: Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX in Patients with Menieres Disease
      • Jun 27, 2017: Sound Pharmaceuticals completes enrollment on Meniere's Disease clinical trial
      • Jun 20, 2017: Otonomy to Host Key Opinion Leader Meeting for Investors on Meniere's Disease
      • Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use
      • Jan 19, 2017: Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
      • Aug 01, 2016: Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Meniere Disease Patients
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Meniere Disease, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Products under Development by Companies, H2 2019
  • Table 4: Number of Products by Stage and Target, H2 2019
  • Table 5: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 6: Number of Products by Stage and Route of Administration, H2 2019
  • Table 7: Number of Products by Stage and Molecule Type, H2 2019
  • Table 8: Meniere Disease - Pipeline by IntraBio Ltd, H2 2019
  • Table 9: Meniere Disease - Pipeline by Orbis Biosciences Inc, H2 2019
  • Table 10: Meniere Disease - Pipeline by Otonomy Inc, H2 2019
  • Table 11: Meniere Disease - Pipeline by Quark Pharmaceuticals Inc, H2 2019
  • Table 12: Meniere Disease - Pipeline by Sound Pharmaceuticals Inc, H2 2019
  • Table 13: Meniere Disease - Pipeline by Synphora AB, H2 2019
  • Table 14: Meniere Disease - Dormant Projects, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Meniere Disease, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products by Targets, H2 2019
  • Figure 4: Number of Products by Stage and Targets, H2 2019
  • Figure 5: Number of Products by Mechanism of Actions, H2 2019
  • Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Routes of Administration, H2 2019
  • Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
  • Figure 9: Number of Products by Molecule Types, H2 2019
  • Figure 10: Number of Products by Stage and Molecule Types, H2 2019
Back to Top